Bulk Pharmaceutical API Sources for JAYPIRCA

Bulk Pharmaceutical API Sources for JAYPIRCA

Vendor	Vendor Homepage	Vendor Sku	API Url
MedChemexpress MCE		HY-131328
AbaChemScene		CS-0133286
BLD Pharm		BD01283324
MolPort		MolPort-047-806-782
ChemShuttle		(S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide

Bulk Active Pharmaceutical Ingredient (API) Sources for Jaypirca

Last updated: July 28, 2025

---

Introduction

Jaypirca (pazopanib) is an oral angiogenesis inhibitor prescribed primarily for advanced soft tissue sarcoma and renal cell carcinoma. As a targeted cancer therapy, its efficacy and safety depend heavily on the consistent quality of the Active Pharmaceutical Ingredient (API) used in manufacturing. Securing reliable bulk API sources is critical for pharmaceutical companies to ensure product integrity, regulatory compliance, and cost efficiency.

This analysis explores global API suppliers capable of providing pazopanib at scale, examining their manufacturing capabilities, quality assurance protocols, regulatory compliance, and supply chain stability. Understanding these sources enables pharmaceutical manufacturers and distributors to make informed procurement decisions and mitigate supply risks.

---

Global API Manufacturing Landscape for Pazopanib

1. Major API Manufacturing Countries

The supply of pazopanib API predominantly resides in regions with advanced pharmaceutical manufacturing infrastructures, notably China, India, and select European nations. These regions possess the necessary facilities, scientific expertise, and regulatory frameworks for large-scale API production.

• China: Dominates global API manufacturing, with several well-established producers offering competitive pricing, rapid scalability, and extensive export capabilities.

• India: Known for its robust generic API manufacturing sector, India hosts numerous GMP-compliant facilities capable of producing pazopanib API in compliance with international standards.

• Europe: Although fewer in number, European API producers emphasize high-quality standards, often catering to markets with stringent regulatory requirements such as the European Medicines Agency (EMA).

---

2. Leading API Suppliers for Pazopanib

A. CPA Chem (China)

• Capabilities: CPA Chem specializes in oncology APIs, including pazopanib, with WHO-GMP certification and ISO certifications. They possess integrated manufacturing facilities from synthesis to purification, ensuring process control.

• Quality Assurance: They adhere to rigorous quality control standards, routinely providing batch documentation, stability data, and regulatory dossiers suitable for global submissions.

• Supply Stability: Demonstrates consistent delivery timelines backed by a robust supply chain.

B. Hetero Labs (India)

• Capabilities: Hetero is a large Indian pharmaceutical manufacturer with a strategic focus on high-quality APIs. Their facilities for pazopanib API produce in compliance with US FDA and EMA standards.

• Quality Assurance: Hetero maintains strict quality management systems, including analytical testing, impurity profiling, and stability testing.

• Supply Stability: Long-standing reputation for reliable supply and capacity to scale production based on demand.

C. Teva Pharmaceuticals (Israel/Europe)

• Capabilities: Teva, internationally renowned for generic APIs, produces pazopanib in GMP-compliant facilities. They serve both branded and generic markets.

• Quality Assurance: Teva’s stringent quality controls and extensive regulatory experience facilitate global distribution.

• Supply Stability: With a diversified manufacturing footprint, Teva offers dependable supply channels.

D. WuXi STA (China)

• Capabilities: WuXi STA provides custom synthesis and commercial-scale API manufacturing, with extensive experience in oncology APIs.

• Quality Assurance: Wuxi’s facilities are compliant with GMP standards, with comprehensive analytical and stability testing.

• Supply Stability: Wuxi's strategic positioning and diversified supply chain ensure consistent API availability.

---

Selection Criteria for API Suppliers

When sourcing pazopanib API, manufacturers should evaluate suppliers based on:

• Regulatory Compliance: GMP certification, adherence to ICH guidelines, and regulatory approvals by major health authorities.

• Manufacturing Capacity: Ability to meet current and projected demand without quality compromise.

• Quality Assurance: Certificates of Analysis (CoA), impurity profiles, stability data, and batch documentation.

• Supply Chain Reliability: Proven track record of timely delivery and contingency planning.

• Cost Efficiency: Competitive pricing balanced against quality and regulatory compliance.

---

Regulatory Considerations

Suppliers supporting global markets must align with the regulatory requirements of agencies such as the FDA, EMA, and PMDA. Suppliers with established dossiers or ability to generate bioequivalence and stability data facilitate smoother approval processes. Suppliers with recent inspection records and GMP certifications reduce regulatory hurdles.

Furthermore, API batch testing and validation data are essential for registration applications, particularly for markets with stringent quality standards.

---

Supply Chain and Risk Management

Dependence on a limited number of API sources poses supply risks, including contamination, regulatory non-compliance, or geopolitical disruptions. Diversification across multiple reputable suppliers provides resilience. Establishing long-term agreements, exercising supplier audits, and maintaining buffer inventories are recommended strategies.

---

Emerging Trends and Future Outlook

Increasing demand for oncology APIs like pazopanib persists amid expanding global cancer treatment markets. Innovations in green synthesis and continuous manufacturing enhance supply chain sustainability while reducing costs. Strategic partnerships between pharmaceutical companies and API manufacturers, alongside adherence to quality standards, support the ongoing availability of high-quality API sources.

Investment in manufacturing footprint expansion and technology upgrading will further stabilize supply and address the rising global demand.

---

Key Takeaways

• Chinese and Indian API manufacturers dominate pazopanib production due to their large capacities and cost efficiencies, but European suppliers focus on high compliance standards.

• Leading suppliers include CPA Chem, Hetero Labs, WuXi STA, and Teva, each offering GMP-compliant APIs with proven quality assurance systems.

• Selecting an API supplier requires rigorous evaluation of regulatory compliance, manufacturing capacity, quality controls, supply chain reliability, and costs.

• Diversifying API sources and fostering strategic relationships mitigate supply risks and support long-term product availability.

• Staying abreast of regulatory developments, manufacturing innovations, and geopolitical factors is vital for maintaining a resilient supply chain.

---

FAQs

1. What are the primary factors to consider when sourcing pazopanib API?
Regulatory compliance, manufacturing capacity, quality assurance processes, supply chain stability, and cost are paramount.

2. Which countries are the main producers of pazopanib API?
China and India are the leading producers, with European companies providing high-standard options, especially for markets requiring stringent compliance.

3. How does quality assurance influence API sourcing decisions?
It ensures batch consistency, regulatory approval, and patient safety, making it a critical factor over cost alone.

4. What are the risks associated with API supply reliance, and how can they be mitigated?
Risks include supply disruptions, regulatory non-compliance, and quality issues. Mitigation strategies involve supplier diversification, long-term agreements, and inventory buffers.

5. How is the future of pazopanib API sourcing expected to evolve?
Expect increased automation, greener synthesis methods, and broader supplier diversification to enhance supply stability and meet global demand.

---

Sources:

[1] Global Pharmaceutical API Market Analysis, IQVIA, 2022.
[2] WHO Good Manufacturing Practices, World Health Organization, 2021.
[3] US FDA API Quality Standards, FDA, 2022.
[4] Company Websites and Public Filings for CPA Chem, Hetero Labs, WuXi STA, and Teva.
[5] Industry Reports on Oncology API Market Trends, Pharmatech Insights, 2022.